30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

30006000330066003300660036007200
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
Lung Cancer - Non-Small Cell Lung Cancer
NTRK family rearrangements are seen in about 3% of non-small cell lung cancers.LOXO-101 has demonstrated considerable remission rates in the treatment of patients with a wide range of tumors that are fused with NTRK family genes.
Soft Tissue Tumors
NTRK rearrangement spindle cell tumors are rare soft tissue tumors that are molecularly characterized by NTRK rearrangements, with the majority of cases involving NTRK1 gene translocations, and partner genes including LMMA, TMP, TPK, and SOSTM1. A few cases involve NTRK2 and NTRK3 gene translocations, including EML4, STRN, and so on.
Other solid tumors
Targeted therapy: the official website of NMPA shows that NTRK inhibitors larotrectinib and entrectinib were approved and marketed for the treatment of adult and pediatric patients with solid tumors carrying NTRK fusion genes.